|
WO2016113203A1
|
|
Engineered t cells and uses therefor
|
|
WO2015104406A2
|
|
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
TW201524994A
|
|
Novel binding proteins for PCSK9
|
|
US2015369821A1
|
|
Novel lipocalin-mutein assays for measuring hepcidin concentration
|
|
WO2014076321A1
|
|
Novel specific-binding polypeptides and uses thereof
|
|
US2014080177A1
|
|
Anticalins
|
|
WO2013174783A1
|
|
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
WO2013104586A1
|
|
Methods for preventing, treating or diagnosing disorders
|
|
AU2012350654A1
|
|
Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
|
|
WO2013068590A1
|
|
Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization
|
|
WO2012136685A1
|
|
Methods and compositions for anti-vegf and anti-c-met therapy
|
|
AU2011331232A1
|
|
Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
|
|
AU2011290751A1
|
|
Binding proteins for Hepcidin
|
|
AU2011203057A1
|
|
Muteins of tear lipocalin and methods for obtaining the same
|
|
WO2011154420A2
|
|
Tear lipocalin muteins binding il-4 r alpha
|
|
CN102770764A
|
|
Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target
|
|
CN102612362A
|
|
Controlled release formulations of lipocalin muteins
|
|
RU2515063C2
|
|
Muteins of tear lipocalin, possessing affinity to human c-met receptor tyrosine kinase and methods of obtaining them
|
|
EP2046820A2
|
|
Muteins of tear lipocalin and methods for obtaining the same
|
|
CN101516907A
|
|
Muteins of tear lipocalin and methods for obtaining the same
|
